Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+)

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years

حداقل ۳ — حداکثر ۲۰ • واحد: g/dL

حداقل ۰.۱ — حداکثر ۵۰۰ • واحد: ×10⁹/L

حداقل ۱ — حداکثر ۲۰۰۰ • واحد: ×10⁹/L

حداقل ۰ — حداکثر ۱۰۰ • واحد: %

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mipss70 score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–2
  • Intermediate-1 Risk3–4
  • Intermediate-2 Risk5–6
  • High Risk7–15
Direct Clinical Answer

The Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include age years. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Stratifies risk for patients with overt primary myelofibrosis (PMF) using clinical, laboratory, and molecular genetic parameters. This enhanced prognostic system incorporates high molecular risk mutations to improve risk stratification beyond traditional clinical factors.

Clinical Indication

The Mutation-Enhanced International Prognostic Score System (MIPSS70/MIPSS70+) is indicated for bedside clinical practice to support Stratifies risk for patients with overt primary myelofibrosis (PMF) using clinical, laboratory, and molecular genetic parameters. This enhanced prognostic system incorporates high molecular risk mutations to improve risk stratification beyond traditional clinical factors.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Risk categories guide treatment decisions including timing of allogeneic stem cell transplantation.

Formula & Variables:

MIPSS70 score = Age points + Hemoglobin points + WBC points + Platelet points + Blast points + Constitutional symptoms points + High molecular risk points (+ Very high molecular risk points for MIPSS70+)

Input Parameters

NameTypeRequiredDescription
age_yearsintegerYesPatient age in years. Age is a key prognostic factor in primary myelofibrosis(years)
hemoglobinfloatYesHemoglobin level in g/dL. Anemia is an independent prognostic factor in myelofibrosis(g/dL)
white_blood_countfloatYesWhite blood cell count in ×10⁹/L. Leukocytosis indicates disease burden and poor prognosis(×10⁹/L)
platelet_countfloatYesPlatelet count in ×10⁹/L. Thrombocytopenia is associated with advanced disease and poor prognosis(×10⁹/L)
circulating_blastsfloatYesPercentage of circulating blasts in peripheral blood. Higher blast percentage indicates disease progression(%)
constitutional_symptomsstringYesPresence of constitutional symptoms (weight loss >10% in 6 months, night sweats, fever). Indicates advanced disease
high_molecular_risk_mutationsstringYesPresence of high molecular risk mutations (ASXL1, EZH2, SRSF2, IDH1/2). These mutations confer poor prognosis
very_high_molecular_riskstringNoPresence of very high molecular risk mutations (≥2 high-risk mutations or specific mutation patterns). Used in MIPSS70+ version

Score Interpretation & Guidance

RangeStageDescription
0–2Low RiskLow risk primary myelofibrosis
3–4Intermediate-1 RiskIntermediate-1 risk primary myelofibrosis
5–6Intermediate-2 RiskIntermediate-2 risk primary myelofibrosis
7–15High RiskHigh risk primary myelofibrosis

Evidence-Based References (EBM)

  • Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310-318. doi: 10.1200/JCO.2017.76.4886.DOI: 10.1200/JCO.2017.76.4886
  • Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36(17):1769-1770. doi: 10.1200/JCO.2018.78.9867.DOI: 10.1200/JCO.2018.78.9867
  • Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8. doi: 10.1182/blood-2009-09-245837.DOI: 10.1182/blood-2009-09-245837

Related calculators